Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer
Bladder Cancer · 2026-06 · 12 (2)
DOI: 10.1177/23523735261447111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder Cancer, online erschienen am 13.05.2026. Verfasst von Adam Cole und 2 weiteren Autor:innen. Beteiligte Einrichtung: PathNet, Little Rock, AR, USA. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ferring Pharmaceuticals Inc., Parsippany, NJ.
Abstract (Originalsprache)
Background
Concomitant carcinoma in situ (CIS) with high-grade papillary urothelial carcinoma impacts patient risk stratification and treatment. However, on identification of a high-grade papillary lesion, pathologists may be disinclined to search for possible CIS. Several newer agents for bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer (NMIBC) are indicated specifically for patients with CIS ± papillary tumors; hence failure to detect/report CIS may limit treatment options.
Objective
To assess CIS frequency in patients with high-grade Ta/T1 NMIBC.
Methods
In this retrospective cohort study, transurethral resection of bladder tumor biopsy specimens with an accompanying diagnosis of high-grade papillary NMIBC without CIS were identified in the PathNet database (2023–2024) and re-reviewed by a single pathologist for the presence of concomitant CIS.
Results
In total, 316 cases of high-grade papillary urothelial carcinoma (254 Ta, 62 T1 disease) were identified for re-review. Mean patient age was 73 (range 27–93) years; 81.0% of patients were male. On re-review, CIS was identified in 80 cases (25.3%, 95% CI 20.8%–30.4%). CIS frequency was higher in T1 disease (19/62 cases [30.6%]) vs Ta disease (61/254 cases [24.0%]). Among the 8 pathologists who performed the initial review, CIS-positivity rates in their individual biopsy samples varied from 15.0% (6/40) to 66.7% (2/3).
Conclusion
This study suggests that ∼25% of patients with high-grade papillary urothelial carcinoma may have unreported CIS. Close communication between the urologist and pathologist is crucial in ensuring specific exclusion of CIS in all bladder specimens, since a diagnosis of concomitant CIS may impact patient management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PathNet, Little Rock, AR, USA.
- Ferring Pharmaceuticals Inc., Parsippany, NJ, USA.
- Arkansas Urology, Little Rock, AR, USA.
Förderung
- Ferring Pharmaceuticals Inc., Parsippany, NJ
Zitieren
APA
Cole, A., Shoskes, D. A., & Henderson, R. J. (2026). Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer. Bladder Cancer, 12(2). https://doi.org/10.1177/23523735261447111
Vancouver
Cole A, Shoskes DA, Henderson RJ. Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer. Bladder Cancer. 2026;12(2). doi:10.1177/23523735261447111
BibTeX
@article{Cole2026,
author = {Cole, Adam and Shoskes, Daniel A and Henderson, R Jonathan},
title = {Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer},
journal = {Bladder Cancer},
year = {2026},
volume = {12},
number = {2},
doi = {10.1177/23523735261447111}
}
EUVIMED